- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04749979
Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin
February 10, 2021 updated by: Aljazeera Hospital
Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin in IVF Cycles
Estradiol valerate in the form of cycloprogenova™ (white tablet only) was started on day 2 or 3 of cycle with oral dose 4 mg divided on 2 doses in addition to Aspocid 75 mg once daily with folic acid 500 mcg once daily.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
U/S was done on day 9 or 10 of cycle to assess endometrial thickness, then every other day until endometrial thickness of 8 mm or more is reached and when endometrial thickness reaches 8 mm or more FET was planned.
Progesterone in the form of prontogest™ 400 mg vaginal suppository twice dTwo to Four Day 5 Embryos was transferred
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Giza, Egypt
- Aljazeera( Al Gazeera) hospital
-
Contact:
- Mahmoud Alalfy, PhD
- Phone Number: +2 +201002611058
- Email: mahmoudalalfy@ymail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 42 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- PCOS patients according to Rotterdam criteria
- Female age between 20 and 40 years.
- Primary or secondary infertility.
- Body mass index (BMI) between 18 and 40 kg/m2.
Exclusion Criteria:
Ovarian endometriosis.
- Ovarian cysts before induction.
- Known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: giving agonist ( eg. decapeptyl )
Giving women agonist
|
giving agonist
|
Active Comparator: Giving HCG (eg. choriomon )
Giving women HCG
|
giving HCG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the number of good quality embryos
Time Frame: within 5 months
|
how many good quality embryos
|
within 5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 5, 2021
Primary Completion (Anticipated)
June 25, 2021
Study Completion (Anticipated)
July 1, 2021
Study Registration Dates
First Submitted
January 29, 2021
First Submitted That Met QC Criteria
February 10, 2021
First Posted (Actual)
February 11, 2021
Study Record Updates
Last Update Posted (Actual)
February 11, 2021
Last Update Submitted That Met QC Criteria
February 10, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Oocyte
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Agonist (decapeptyl )
-
Kasr El Aini HospitalCompleted
-
Instituto de Investigacion Sanitaria La FeCompletedFemale Urogenital DiseasesSpain
-
Kasr El Aini HospitalCompleted
-
University of AarhusUnknown
-
Sheba Medical CenterCompleted
-
Hopital FochRecruitingEndometriosis | Adenomyosis | Infertility, FemaleFrance
-
University of LahoreCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Completed